HC Wainwright Maintains Buy Rating on Atrium Therapeutics
HC Wainwright maintained its Buy rating and $20 price target on Atrium Therapeutics. The target implies 140.4% upside from the Oct. 27 close of $8.32.
Related stories
Nextensa Sells Luxembourg Office Building for EUR43.5 Million
Nextensa announced the sale of a Luxembourg office building to Centre Hospitalier de Luxembourg for EUR43.5 million.
L impact | EQUITY | Oct 29, 2026, 02:40 PM UTC
Shenzhen Longsys Electronics Reports Quarterly Revenue of RMB 14.63 Billion
M impact | EQUITY | Oct 29, 2026, 02:39 PM UTC
SUMMI Group Delays FY26 Annual Results Publication
SUMMI Group’s FY26 annual results publication is delayed due to audit procedures.
M impact | EQUITY | Oct 29, 2026, 02:39 PM UTC
Shenzhen Longsys Electronics Reports Quarterly Net Profit of RMB 3.74 Billion
M impact | EQUITY | Oct 29, 2026, 02:39 PM UTC
Insperity Shares Fall More Than 13% After Q3 Results and Updated Guidance
Insperity shares fell more than 13% after the company reported third-quarter results and updated its 2026 adjusted earnings guidance.
M impact | EQUITY | Oct 29, 2026, 02:38 PM UTC
Novavax Earns $125 Million Milestone Payment From Sanofi Vaccine Trial
Novavax earned a $125 million milestone payment from Sanofi's Phase 3 vaccine trial in Europe.
M impact | EQUITY | Oct 29, 2026, 02:38 PM UTC